|
Q4 2010
|
|
|
|
12/30/10
|
80.6% (54/67)
|
17%
|
|
12/21/10
|
80.3% (53/66)
|
10%
|
|
12/20/10
|
80% (52/65)
|
9%
|
|
12/17/10
|
80% (51/64)
|
10.5%
|
|
12/8/10
|
80% (48/60)
|
15%
|
|
12/8/10
|
79.7% (47/59)
|
8%
|
|
12/3/10
|
79.3% (46/58)
|
18%
|
|
11/29/10
|
79% (45/57)
|
Loss
|
|
11/20/10
|
80.4% (45/56)
|
20%
|
|
11/20/10
|
80% (44/55)
|
< 4%
|
|
11/16/10
|
79.6% (43/54)
|
300%
|
|
11/12/10
|
79.2% (42/53)
|
Loss
|
|
10/17/10
|
Seattle Genetics (SGEN)
|
33%
|
|
10/15/10
|
80.8% (42/52)
|
< 4%
|
|
10/5/10
|
80.4% (41/51)
|
41%
|
|
10/5/10
|
80% (40/50)
|
< 4%
|
|
10/5/10
|
79.6% (39/49)
|
9%
|
|
Q3 2010
|
|
|
|
9.30.10
|
79.2% (38/48)
|
12%
|
|
9.28.10
|
BioNiche (BNHLF)
|
28%
|
|
9.24.10
|
Anika (ANIK)
|
10.7%
|
|
9.23.10
|
Delcath (DCTH)
|
19%
|
|
9.23.10
|
iShares Biotech (IBB)
|
8.5%
|
|
9.21.10
|
78.7% (37/47)
|
5%
|
|
9.10.10
|
78.3% (36/46)
|
5%
|
|
9.9.10
|
Symantec (SYMC)
|
10%
|
|
9.3.10
|
KMG Chemicals (KMGB)
|
7.5%
|
|
9.3.10
|
77.8% (35/45)
|
7.5%
|
|
9.3.10
|
Innophos (IPHS)
|
13%
|
|
8.31.10
|
BioScrip (BIOS)
|
17.7%
|
|
8.31.10
|
77.3% (34/44)
|
17.7%
|
|
8.30.10
|
77% (33/43)
|
Loss
|
|
8.26.10
|
Cereplast (CERP)
|
18%
|
|
8.26.10
|
78.6% (33/42)
|
18%
|
|
8.25.10
|
Gold (GLD)
|
< 4%
|
|
8.25.10
|
78% (32/41)
|
< 4%
|
|
8.11.10
|
Jazz Pharma (JAZZ)
|
20%
|
|
8.11.10
|
77.5% (31/40)
|
20%
|
|
8.11.10
|
77% (30/39)
|
Loss
|
|
8.6.10
|
81% (30/37)
|
4%
|
|
8.5.10
|
80.5% (29/36)
|
23%
|
|
8.3.10
|
Cypress Biosciences (CYPB)
[DK’s Results]
|
200%
|
|
8.3.10
|
80% (28/35)
|
< 4%
|
|
8.2.10
|
79.4% (27/34)
|
19%
|
|
7.29.10
|
Response Genetics (RGDX)
|
100%+
|
|
7.29.10
|
78.8% (26/33)
|
5%
|
|
7.19.10
|
Cypress Biosciences (CYPB)
78.1% (25/32)
|
140%
|
|
Q2 2010
|
|
|
|
6.19.10
|
77.4% (24/31)
|
30%
|
|
6.18.10
|
76.7% (23/30)
|
10%
|
|
6.18.10
|
75.8% (22/29)
|
< 4%
|
|
6.18.10
|
75% (21/28)
|
< 4%
|
|
6.18.10
|
74% (20/27)
|
7%
|
|
6.18.10
|
73.1% (19/26)
|
9%
|
|
6.18.10
|
72% (18/25)
|
14%
|
|
6.18.10
|
70.8% (17/24)
|
11%
|
|
6.18.10
|
69.5% (16/23)
|
9%
|
|
6.18.10
|
68.1 % (15/22)
|
< 4%
|
|
6.18.10
|
66.7% (14/21)
|
6.7%
|
|
6.18.10
|
65% (13/20)
|
< 4%
|
|
6.18.10
|
63.1% (12/19)
|
Loss
|
|
6.3.10
|
85.7% (12/14)
|
37.5%
|
|
6.1.10
|
84.6% (11/13)
|
11%
|
|
6.1.10
|
83.3% (10/12)
|
16%
|
|
5.14.10
|
81.8% (9/11)
|
Loss
|
|
5.14.10
|
90% (9/10)
|
13%
|
|
5.12.10
|
88.9% (8/9)
|
31%
|
|
5.11.10
|
87.5% (7/8)
|
70%
|
|
5.5.10
|
85.7% (6/7)
|
143%
|
|
4.29.10
|
83.3% (5/6)
|
12%
|
|
4.27.10
|
80% (4/5)
|
39%
|
|
4.26.10
|
75% (3/4)
|
11%
|
|
4.26.10
|
Portfolio Results from 4/26/2010 (PDF)
|
|
|
4.14.10
|
67% (2/3)
|
10%
|
|
4.14.10
|
50% (1/2)
|
30%
|
|
4.8.10
|
Portfolio Results from 4/8/2010 (PDF)
|
|
|
Q1 2010
|
|
|
|
3/30/10
|
0% (0/1)
|
Loss
|
|
3/12/10
|
RXI’s Official Launch
|
|
|
3/5/10
|
Portfolio Results from 3/5/2010 (PDF)
|
|
|
Q4 2009
|
|
|
|
12.15.09
|
Portfolio Results from 12/15/2009
|
|
|
11.16.09
|
Portfolio Results from 11/16/2009
|
|
|
10.12.09
|
Portfolio Results from 10/12/2009
|
|
|
Q3 2009
|
|
|
|
9.16.09
|
Portfolio Results from 9/16/2009
|
|
|
9.11.09 (1)
9.11.09 (2)
|
Portfolio Results from 9/11/2009
|
|
|
8.24.09
|
Portfolio Results from 8/24/2009
|
|
|
8.4.09
|
Portfolio Results from 8/4/2009
|
|
|
Q2 2009
|
|
|
|
6/1/09
|
Cell Therapeutics (CTIC)
|
2,850%
|
